Tiny $35M Biotech Leverages Proven Technology to Potentially Revolutionize How Diabetes and Obesity Medications Are Delivered (NASDAQ:PYPD)PolyPid ...

Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval when selling compounded version of tirzepatide.

Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

In this episode of The NBR Podcast with Simon Shepherd: Obesity. Conservatively, it's a two-billion-dollar problem. But the ...

Cipla Limited is planning to enter the weight management segment in India, announced the company’s MD and global CEO Umang ...

Mumbai: Mumbai-based pharma giant Cipla is gearing up to make an entry into India's rapidly growing weight management market, ...

This year, drug companies have been living under a cloud of uncertainty created by the Trump administration. Threats of tough ...

The pharma major is also strengthening its presence in the central nervous system (CNS) therapeutic area, Vohra stated ...

Cipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and Danish firm Novo Nordisk.